Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019

Overview

The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19 infection.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 13, 2023

Interventions

  • Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
    • sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
  • Drug: Placebo
    • sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Arms, Groups and Cohorts

  • Experimental: Sacubitril/valsartan
    • Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability. Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally. Other Name: LCZ696
  • Placebo Comparator: Placebo
    • Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability. Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, adminstered twice daily orally.

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline in high-sensitivity troponin T
    • Time Frame: Baseline, Week 12
  • Change from baseline in soluble ST2
    • Time Frame: Baseline, Week 12

Secondary Measures

  • Change from baseline in C-reactive peptide
    • Time Frame: Baseline, Week 12
  • Change from baseline in PINP
    • Time Frame: Baseline, Week 12
  • Change from baseline in Galectin-3
    • Time Frame: Baseline, Week 12
  • Change from baseline in NT-proBNP
    • Time Frame: Baseline, Week 12
  • Change from baseline in GDF-15
    • Time Frame: Baseline, Week 12
  • Change from baseline in interleukin-6
    • Time Frame: Baseline, Week 12
  • Change from baseline in cardiac MRI measures
    • Time Frame: Baseline, Week 12
  • Change from baseline in focal fibrosis by delayed-enhancement on cardiac MRI
    • Time Frame: Baseline, Week 12
  • Change from baseline in focal fibrosis by percentage of left ventricular myocardial mass on cardiac MRI
    • Time Frame: Baseline, Week 12
  • Change from baseline in EuroQOL-5 dimensions utility score
    • Time Frame: Baseline, Week 12
  • Change from baseline in EuroQOL-5 dimensions visual analog scale
    • Time Frame: Baseline, Week 12

Participating in This Clinical Trial

Inclusion Criteria

1. Patient with a history of laboratory proven-diagnosis of COVID-19 who is 4-16 weeks from their last positive COVID-19 test 2. Systolic blood pressure ≥100 mmHg at screening 3. ≥18 years of age 4. Successful collection of baseline serum biomarkers 5. Successful completion of baseline EQ-5D questionnaire 6. Successful completion of baseline CMR study (CMR sub-study only) 7. High-sensitivity troponin T at or above the level of detection on screening labs 8. Presence of ≥1 of the following: 1. Age ≥60 2. History of atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease 3. Diabetes mellitus (Type 1 or Type 2) 4. Body mass index ≥35 kg/m2 5. eGFR 30-60 ml/min/1.73m2 6. History of atrial fibrillation/flutter Exclusion Criteria:

1. Fever within the past 96 hours of >100.3 degrees Fahrenheit 2. Actively receiving therapy with an angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), aliskiren, or sacubitril/valsartan 3. Last known left ventricular ejection fraction of ≤40% 4. eGFR <30 ml/min/1.73m2 on screening labs, including patients on dialysis therapy 5. Serum potassium >5.0 mEq/L on screening labs 6. Prior intolerance, allergy or angioedema to ACEI, ARB, or sacubitril/valsartan 7. Pregnant or breast-feeding 8. In women of childbearing age, unwillingness to use birth control for the duration of the study 9. History of heart transplant or durable left ventricular assist device 10. Currently implanted permanent pacemaker, defibrillator, or other device that would preclude CMR testing (CMR sub-study only) 11. Currently participating in another trial of an investigational medication or device for COVID-19. 12. Any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Duke University
  • Collaborator
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stephen J Greene, MD, Principal Investigator, Duke University
    • G. Michael Felker, MD, MHS, Principal Investigator, Duke University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.